CS MEDICA A/S (“CS MEDICA” or the “Company”) announces today that the company invites investors, brokers, analysts, and media to a live-streamed session with highlights of the Annual report 2021/2022 and option for questions on Monday the 30th of January at 15:00 CEST.

CS MEDICA will publish its Annual report 2021/2022 on Friday, the 27th of January. The highlights of the report will be presented in a webinar at 15:00 CEST on the following Monday.

Date and time
January 30, 2023, from 15:00 – 15:30 CEST

Webcast link
Live Webcast link >>.

For more information about CS MEDICA, please contact:
Gitte Lund Henriksen, CFO
Phone: + (45) 2774 2280
Email: glh@cs-medica.com
Website: https://www.cs-medica.com/

CS MEDICA A/S is a Danish-based MedTech company committed to improving people’s lives with products that make a difference. We combine science, nature, and passion to deliver innovative alternatives with high efficacy and bioavailability to patients. From autoimmune to stress therapies, we aim to transform healthcare with more effective treatments.

We research, develop, manufacture, commercialize and brand over-the-counter (OTC) products under pharmaceutical legislation. Currently, 21 products with cannabidiol aimed at autoimmune and stress-related diseases have been developed. The first products reached Danish stores in 2020, and now 9 products are available on the European market at more than 500 points of sale. Another 12 products will be launched before the end of 2024, with 11 patent-pending products. The product line surpasses competing products on the market by being located at the intersection of natural products, science, and cannabinoid technology while being registered under pharmaceutical legislation.

CS MEDICA was recognized earlier this year as a company of Europe’s top 10 MedTech companies at European Lifestars Awards as the company both Research & Develop, Manufacture, Distribute and Brand life-supporting medical technologies.

Tags: